NORWALK,
Conn., Sept. 10,
2024 /PRNewswire/ -- LifeSpan Vision Ventures today
announced that it has closed an investment in Remedium Bio.
The biotechnology company is developing a first-in-class
adjustable-dose gene therapy platform called Prometheus™, which can
replace a broad range of multi-protein injection treatments with a
single injection, dose adjustable, gene therapy. The treatment,
which is administered by a subcutaneous injection, is highly safe,
localized, durable, and costs less than many protein-based
therapeutics. Unlike with therapeutic protein injections,
Prometheus™ delivers stable, durable, and consistent protein
expression, eliminating the concentration spikes that can limit the
safety and efficacy of treatments delivered via repeat
injection.
The funding will be used to advance the company's lead
candidate, RMD-1202, towards Phase 1 studies. RMD-1202 delivers a
GLP-1 receptor agonist and demonstrates weight loss, glycemic
control, and insulin response superior to daily GLP-1 protein
injections - with a potentially increased safety and tolerability
profile. The platform can deliver a broad range of proteins, from
peptides to antibodies and Remedium is developing additional
therapies across musculoskeletal, immunology, and neurology
disorders.
Andrew Worden, Founding Partner
at LifeSpan Vision Ventures, said "Our mission is to invest in
companies that support and accelerate the development of therapies
that extend healthspan and address age-related challenges. We
believe that Remedium's technology can be applied across a broad
range of age-related diseases and opens the potential of gene
therapy to vast markets. We are delighted to be supporting Frank
and his team to take the company to the next level."
Frank Luppino, President and CEO
of Remedium, stated "We are extremely excited to welcome Lifespan
Vision Ventures as an investor in Remedium Bio. Our Prometheus™
platform is a significant advance in genetic medicine, one that
brings the benefits of gene therapy to large unmet needs affecting
how we age. Lifespan, with their strong grounding in the science
and experience growing innovative companies, is an ideal partner to
support Remedium as we enter an exciting new phase in our
evolution."
About Remedium Bio
Remedium is a biotechnology company focused on the development
of treatments for large unmet clinical needs. To enable this, we
developed a revolutionary gene therapy platform, which enables
safe, effective, and durable delivery of therapeutic genes while
allowing for simple post-treatment dose adjustment. The Prometheus™
adjustable gene therapy platform enables replacement of a broad
range of subcutaneously administered protein treatments with a
single injection, adjustable dose gene therapy. The system has an
exceptionally high degree of specificity and remains localized to
the site of the subcutaneous injection, offering a safe and
durable, single injection alternative, at a fraction of the current
protein-based therapeutic treatment cost. Remedium's pipeline
includes several disease modifying treatments with unprecedented
efficacy in the fields of endocrinology (weight loss and type 2
diabetes), immunology, neurology, and musculoskeletal diseases.
For more information,
visit https://www.remedium-bio.com/
About LifeSpan Vision Ventures
LifeSpan Vision Ventures is a forward-thinking venture capital
firm specializing in investments within the aging and longevity
space. Our mission is to support and accelerate the development of
innovative therapies that extend healthspan, improve the quality of
life for individuals as they age, and address age-related
challenges. Through strategic partnerships and investments, we aim
to shape a future where aging is met with vitality, resilience, and
endless possibilities.
Contact: Harry Robb, Analyst:
harry.robb@lifespanvision.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lifespan-vision-ventures-invests-in-remedium-bio-302243756.html
SOURCE LifeSpan Vision Ventures